key: cord-0780616-41um8zix authors: Yu, Jiong; Lu, Xuan; Tong, Ling; Shi, Xiaowei; Ma, Jing; Lv, Feifei; Wu, Jian; Pan, Qiaoling; Yang, Jinfeng; Cao, Hongcui; Li, Lanjuan title: Interferon‐α‐2b aerosol inhalation is associated with improved clinical outcomes in patients with coronavirus disease‐2019 date: 2021-05-24 journal: Br J Clin Pharmacol DOI: 10.1111/bcp.14898 sha: 56eab7b5adec14c98d99feebf41494e96bfa265d doc_id: 780616 cord_uid: 41um8zix AIMS: Type 1 interferon (IFN) is used to treat patients with coronavirus disease‐2019 (COVID‐19) but robust supporting evidence is lacking. We investigated the association between IFN‐α‐2b and the clinical outcomes of patients with COVID‐19. METHODS: A total of 1401 patients were enrolled, with 852 (60.8%) patients receiving 5 000 000 U of IFN‐α‐2b via aerosol inhalation twice daily. The primary outcome was a composite measure consisting of mechanical ventilation, intensive care unit (ICU) admission and death. A subgroup analysis was performed to investigate the impact of the IFN‐α‐2b initiation schedule on symptom onset. RESULTS: The risk probability for crude endpoints was lower in the IFN‐α‐2b group (3.8%) than in the non‐IFN‐α‐2b group (9.3%, P < .001). After adjusting the confounding factors, IFN‐α‐2b therapy achieved a reduction of 64% in occurrence of endpoint events (hazard ratio, 0.36; 95% confidence interval [CI], 0.21–0.62). In the subgroup analysis, compared with patients who received IFN‐α‐2b treatment 0–2 days after symptom onset, the hazard ratio for endpoints was 2.2 (95% CI, 0.43–11.13) in patients who received the therapy 3–5 days after symptom onset, 5.89 (95% CI, 0.99–35.05) in patients who received the therapy 6–8 days after symptom onset, and remained at a high level thereafter. CONCLUSIONS: IFN‐α‐2b aerosol inhalation therapy may be associated with improved clinical outcomes in patients with COVID‐19, and delayed IFN‐α‐2b intervention was associated with increased probabilities of risk events. Further randomized clinical trials are needed to validate the preliminary findings of this study. At the end of December 2019, an outbreak of pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in China, subsequently giving rise to a global outbreak. 1 As of 28 April 2020, over 3 000 000 cases of coronavirus disease-2019 have been confirmed worldwide, causing more than 200 000 deaths. The efficacy of broad-spectrum or targeted antivirals on SARS-CoV-2 replication and COVID-19 prognosis is under investigation in randomized clinical trials. 2 Type 1 interferon (IFN) is a non-specific antiviral agent and is widely used to treat emerging viral infections for which no specific drug or vaccine is available. Principal investigator: The authors confirm that the Principal Investigator for this paper is Dr Hongcui Cao. The study uses only anonymous data for analysis and without any individual patient information. IFN therapy reportedly improves the outcomes of Middle East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV infections. [3] [4] [5] [6] [7] [8] In vitro, SARS-CoV-2 is substantially more sensitive to IFN-I than MERS-CoV or SARS-CoV. 9 Therefore, IFN is likely to be effective against COVID- 19 . IFN has been approved by multiple countries for the treatment of COVID-19, 9, 10 for which 5 000 000 U of IFN-α-2b by vapor inhalation twice daily is recommended in China. However, the therapeutic effect of IFN-α-2b on COVID-19 is unclear and needs to be evaluated because there is no specific antiviral therapy. Also, the timing of IFN treatment greatly influences the clinical outcomes of coronavirus infection. 3, 4, 11 Here we investigated the association between IFN-α-2b aerosol inhalation, the clinical outcomes of patients with COVID-19 and the effect of the IFN initiation schedule on symptom onset. The following data were collected from the electronic medical records: epidemiological, demographics, laboratory findings, comorbidities, time from illness onset to hospital admission, time to first dose of antivirals, chest radiological findings on admission, time of the first negative result of a pharyngeal swab, and the duration of hospital stay, with verification by independent physicians. Clinical data were obtained at admission, and laboratory data within 24 hours of admission. COVID-19 cases were confirmed by sequencing or reverse transcriptase-polymerase chain reaction of throat-swab specimens from the upper respiratory tract. The clinical outcomes were followed until 15 March 2020. IFN-α-2b treatment comprised 5 000 000 U via aerosol inhalation twice daily. Patients who received only one dose of IFN-α-2b before reaching an endpoint were included in the IFN-α-2b treatment group. Other treatments included supportive and complications treatments and were conducted according to the guidelines for the Diagnosis and Treatment of COVID-19 of the National Health Commission (seventh edition). The patients were classified as mild, moderate, severe or critical according to the guidelines on the diagnosis and treatment of COVID-19. Based on the clinical information, we classified patients with COVID-19 as moderate (mild or moderate), severe or critical. The onset of COVID-19 was defined as the time when symptoms were first noticed. Patients who tested negative for SARS-CoV-2 in respiratory samples on two consecutive days were considered not to be shedding virus, and the negative time was defined as the day of the first negative test. The composite endpoint was defined as at least one of the following: (1) respiratory failure requiring mechanical ventilation, (2) other organ failure and need for intensive care unit (ICU) monitoring and treatment, and (3) death. 12 If the patient met several criteria for an event, the calculation was based on the time of the first criterion. The duration of hospitalization and the interval from symptom onset or admission to a negative nucleic acid test were also examined. Furthermore, the association between days from onset to IFN-α-2b therapy and clinical outcomes was assessed. Continuous variables are expressed as means and standard deviation or medians and interquartile range (IQR) and were compared by t-test or Mann-Whitney U-test, as appropriate. Categorical variables are expressed as percentages and were evaluated by chi-squared test or What is already known about this subject • Type 1 interferon is a non-specific antiviral and is widely used to treat patients with COVID-19 in China, but robust supporting evidence is lacking. • We investigated the association between IFN-α-2b and the clinical outcomes of patients with COVID-19. • IFN-α-2b aerosol inhalation was associated with improved clinical outcomes of patients with COVID-19. • Earlier IFN-α-2b intervention may be associated with a lower risk of worse outcomes. Fisher exact test. The log-rank test was used to evaluate differences in event-free survival between the two groups. A Cox regression analysis adjusted for the benchmark covariate was conducted to assess the robustness of the results if the proportional risk assumption held. Results are expressed as hazard ratios (HRs) and 95% confidence intervals (CIs). For non-linear relations, we used restricted cubic spline Cox regression analyses to assess the relationship between the initiation time of IFN-α-2b treatment and the clinical outcome after adjusting for sex, age, smoking status, CRP, NLR, other antivirals, clinical type at admission and comorbidities. Statistical analysis was performed using SPSS version 19.0 (IBM, Armonk, NY) and R version 3.4 (R Foundation, Vienna, Austria) software. All tests were two-tailed and P < .05 was considered to indicate statistical significance. We performed further sensitivity analyses to assess the robustness of the results. First, mechanical ventilation or ICU monitoring without death were considered component endpoints and were analysed separately. Second, the outcome was examined in 12 prespecified subgroups defined according to the following baseline characteristics: no). Third, among the 1401 patients eligible for analysis, five received only one dose of IFN-α-2b before the endpoint event, and 549 did not receive IFN-α-2b. After the main analysis, we compared the 847 participants who received more than one dose of IFN-α-2b with the 549 who did not receive the drug. Finally, following the primary analyses, we performed a propensity score analysis to minimize the effect of IFN-α-2b treatment selection bias and to control for potential confounding factors. 13 3 | RESULTS Table 1 , and the patients with missing CRP and/or NLR data are shown in Table S1 in the Supporting Information. (Table 3) . Compared to the non-IFN-α-2b treatment group, the IFN-α-2b treatment group had a shorter median interval from admission to a negative nucleic acid test (13 vs. 14 days, P < .001) and from symptom onset to first negative nucleic acid test (17 vs. 20 days, P < .001, Table 2 ). The duration of hospitalization of discharged patients differed significantly between the two groups (17 vs. 18 days, P = .003) ( Table 2 ). To determine whether the findings were robust to potential confounders, we performed analyses stratified by prespecified subgroups; the analyses were adjusted for all variables other than the stratification variable. In the IFN-α-2b treatment group, the risk of composite endpoint events was lower than that of the non-IFN-α-2b treatment group irrespective of subgroup (HR 0.17-0.55) (Figure 3 ). (Table 3) . After PS matching, the median intervals from admission to a negative nucleic acid test (13 vs. 14 days, P = .530), hospitalization duration (17 vs. 18 days, P = .668), and the interval from symptom onset to a negative nucleic acid test (18 vs. 20 days, P = .052) were not significantly different between the two groups ( Table 2 ). The median time from symptom onset to IFN-α-2b treatment was Cox regression showed a spline at 7 days, which enabled the time-HR relationships before and after to be modelled as the following two linear relations: (1) the HR for composite endpoints increased up to around 7 days (from onset to treatment) and (2) was thereafter maintained at a high but constant level, resulting in an approximately flat slope at > 7 days ( Figure S4 in the Supporting Information). Specifically, compared with patients who received IFN-α-2b treatment 0-2 days after symptom onset, the hazard ratio for composite endpoints was 2.2 (95% CI, 0.43-11.13) in patients who received the (Table 4 , Figure S4 in the Supporting Information). The characteristics of patients with COVID-19 who received IFN-α-2b treatment stratified by onset-to-treatment interval are summarized in Table S4 in the Supporting Information. Our results suggested that IFN-α-2b in combination with standard treatment improves the clinical outcomes of patients with COVID-19. This clinical benefit remained evident in all subgroups after adjusting for confounding factors. Also, IFN-α-2b therapy reduced the frequency of composite endpoint events by 61%. Moreover, the effect was enhanced by 64% after adjusting for confounding factors. In a subgroup analysis of patients who received IFN-α-2b, we explored the association between the IFN-α-2b initiation schedule and clinical outcomes; delayed interferon intervention was associated with increased probabilities of risk events. consistent results from different statistical models. However, IFN-α-2b treatment was not randomly assigned, and potential unmeasurable confounding factors may have biased the results. Second, there is no effective indicator of whether an inhaled dose is sufficient, but it may be possible to use the serum interferon levels for this purpose. Third, the data were collected retrospectively through electronic medical record system, and information like side effects data were not obtained. Thus the other side effects of IFN-α-2b treatment could not be assessed. A novel coronavirus from patients with pneumonia in China A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19 IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset The severe acute respiratory syndrome coronavirus nucleocapsid inhibits type I interferon production by interfering with TRIM25-mediated RIG-I ubiquitination Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoVinfected rhesus macaques Type 1 interferons as a potential treatment against COVID-19 Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19) SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues Clinical characteristics of coronavirus disease 2019 in China Reporting and guidelines in propensity score analysis: a systematic review of cancer and cancer surgical studies IFITM-family proteins: the cell's first line of antiviral defense Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19 Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan Middle East respiratory syndrome coronavirus nucleocapsid protein suppresses type I and type III interferon induction by targeting RIG-I signaling Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury A pneumonia outbreak associated with a new coronavirus of probable bat origin Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade Recombinant human ACE2: acing out angiotensin II in ARDS therapy Inhibition of novel beta coronavirus replication by a combination of interferon-alpha2b and ribavirin Weak induction of interferon expression by severe acute respiratory syndrome coronavirus 2 supports clinical trials of interferon-λ to treat early COVID-19 SUPPORTING INFORMATION Additional supporting information may be found online in the Supporting Information section at the end of this article. How to cite this article The authors have no conflicts of interest to declare.CONTRIBUTORS H.C. and L.L. were responsible for the concept and study design. J.Y., X.L., L.T., X.S., J.M., F.L., J.W., Q.P. and J.Y. acquired the data and prepared the manuscript. J.Y., X.L. and L.T. analysed the data and J.Y. and L.T. were responsible for the Statistical analysis. All the authors reviewed and approved the final manuscript. The data supporting the findings of this study are available from the corresponding author upon reasonable request. https://orcid.org/0000-0002-6604-6867